Best Peptides for Sexual Health
The one FDA-approved compound in this space, and everything positioned next to it.
How this is graded
Every compound below carries a REGEN research grade, from S (regulatory approval behind the use it is bought for) down to F (no clinical evidence). Ordering follows that grade rather than search volume, so the compound at the top is the one with the most evidence, not the one most often sold. Doses are those reported in published protocols and are not recommendations.
1. PT-141
PT-141 (bremelanotide) is a melanocortin receptor agonist that works centrally in the brain to increase sexual desire and arousal, unlike PDE5 inhibitors (e.g. sildenafil) that act on blood flow. It is FDA-approved for hypoactive sexual desire disorder in premenopausal women and is used off-label by men. Effects are dose- and timing-dependent and taken before activity rather than daily. Common side effects include nausea and transient flushing. Used situationally, not as part of a chronic stack.
- Libido (grade S) — 2 cited studies through 2019
Strongest study: Kingsberg RECONNECT phase 3, Obstet Gynecol (2019) — significant improvement in desire score (FSFI-D) + reduction in distress (FSDS-DAO) vs placebo over 24 wks · N=1247
2. Kisspeptin-10
Kisspeptin-10 is a synthetic decapeptide corresponding to the active C-terminal fragment of the human KISS1 gene product. It activates the KISS1R (GPR54) receptor on GnRH neurons, triggering pulsatile GnRH release and downstream LH/FSH secretion — placing it upstream of the entire hypothalamic-pituitary-gonadal (HPG) axis. It's studied in reproductive endocrinology and fertility research, and more recently in libido and HPG-axis research contexts. No formal human dosing protocol or FDA approval exists; it's sold only as a research compound.
3. Oxytocin
Oxytocin is a nine-amino-acid neuropeptide produced in the hypothalamus and released by the posterior pituitary, best known for its roles in labor, lactation, and social bonding. Its synthetic form is FDA-approved (as Pitocin/Syntocinon) for inducing labor and managing postpartum hemorrhage — a well-established, decades-old obstetric drug. Separately, intranasal oxytocin has become a popular research and self-experimentation compound for social bonding, trust, and stress-response research, an application that is not FDA-approved and rests on a much thinner evidence base than its obstetric use.
4. Gonadorelin
Gonadorelin is a synthetic version of gonadotropin-releasing hormone (GnRH), the hypothalamic signal that triggers the pituitary to release LH and FSH, which in turn drive the testes to produce testosterone and sperm. It carries decades-old FDA approval for fertility and diagnostic use, and testosterone-replacement clinics use it — dosed in pulses to mimic the body's natural rhythm — to keep testicular function active alongside exogenous testosterone, similar in purpose to hCG. Head-to-head evidence against hCG, the more established alternative, is mixed, and no study has directly measured its effect on libido itself.
- Fertility / Testicular Function (grade C) — Delemarre-van de Waal 1993: pulsatile GnRH restored testicular growth and sperm production in men with hypogonadotropic hypogonadism (n=38).
Strongest study: Delemarre-van de Waal pulsatile GnRH, clinical study (1993) — Pulsatile GnRH restored testicular growth + sperm production (n=38)
5. hCG (Human Chorionic Gonadotropin)
hCG (human chorionic gonadotropin) is a hormone that mimics LH (luteinizing hormone), the pituitary's own signal telling the testes to produce testosterone. By standing in for that signal, hCG raises a man's endogenous testosterone and keeps sperm production going — restoring the hormonal machinery that testosterone therapy would otherwise suppress. It carries a genuine FDA label dating back to 1962, approved for hypogonadotropic hypogonadism and fertility use, and is one of the most established TRT-adjunct compounds in clinical use. It is not the same as the 'hCG diet' — that use isn't part of its approved label or supporting evidence.
- Testosterone / Fertility Restoration (grade S) — Madhusoodanan 2019 (n=20): hCG monotherapy raised testosterone ~50%, with symptom improvement in half of men. FDA label dates to 1962.
Strongest study: Madhusoodanan hCG monotherapy, clinical study (2019) — Testosterone rose ~50% on hCG alone (n=20)
At a glance
| Compound | Grade | Reported dose | Half-life |
|---|---|---|---|
| PT-141 | Sgrade | 0.5–2 mg · as needed, before activity | ~2-3 hours |
| Kisspeptin-10 | Bgrade | ~100 mcg · research protocol-dependent | Very short (minutes) — unmodified decapeptide with rapid enzymatic clearance |
| Oxytocin | Bgrade | 20–40 IU · intranasal, pre-activity | ~3-5 minutes (rapidly degraded by oxytocinase) |
| Gonadorelin | Cgrade | 100 mcg · 2–3x weekly | ~10-40 minutes |
| hCG (Human Chorionic Gonadotropin) | Sgrade | 250–500 IU · 2–3x weekly | ~24-36 hours |
Frequently asked questions
Which peptide has the most evidence for sexual health?
PT-141, at research grade S. REGEN Research Tier S — official / regulatory approval (FDA or foreign equivalent).
How many compounds are compared here?
5: PT-141, Kisspeptin-10, Oxytocin, Gonadorelin, hCG (Human Chorionic Gonadotropin).
What doses are reported for PT-141?
Published protocols report 0.5–2 mg, as needed, before activity. This is what the literature describes, not a recommendation.
References
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder · Kingsberg SA, et al. · 2019
- Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908. · Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA · 2019
- Safety Profile of Bremelanotide Across the Clinical Development Program. · Clayton AH, Kingsberg SA, Portman D et al. · 2022
- The neurobiology of bremelanotide for the treatment of hypoactive ... · Pfaus JG, Sadiq A, Spana C, Clayton AH · 2022
- Clayton AH, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol. 2019;134(5):909-917. · Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH · 2019
- Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. · Simon JA, Kingsberg SA, Portman D et al. · 2022
- [PDF] Vyleesi (bremelanotide) - accessdata.fda.gov
- Diamond LE, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-38. · Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R · 2006
- Safarinejad MR. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol. 2008;179(3):1066-71. · Safarinejad MR, Hosseini SY · 2008
- Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. · Simon JA, Kingsberg SA, Portman D et al. · 2019
- Bremelanotide - LiverTox - NCBI Bookshelf - NIH
- Molinoff PB, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. · Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY · 2003
- Bremelanotide: First Approval - PubMed · Dhillon S, Keam SJ · 2019
- Induction of testicular growth and spermatogenesis by pulsatile, intravenous administration of gonadotrophin-releasing hormone · Delemarre-van de Waal HA · 1993
- hCG monotherapy for hypogonadism · Madhusoodanan V, et al. · 2019